Major affective disorders including depression and anxiety occur commonly in women of childbearing age and their incidence can increase during and after pregnancy. There is a critical clinical demand for treatment of these disorders, but the balance between treating affective disorders without harming the developing fetus is a difficult one. This has created concern both among women planning pregnancies, and those women who are pregnant already, as well as among families and healthcare providers. Currently, selective serotonin reuptake inhibitors (SSRIs) are the drugs of choice for the treatment of these disorders in pregnant women because of their documented efficacy and mild side effect profile. There is some research concerning SSRI use and pregnancy, which is the focus of this article.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NMC.0000341255.80426.7b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association between gestational selective serotonin reuptake inhibitor (SSRI) treatment and newborn thyroid screen: a large-scale cohort study.
BMC Pediatr
January 2025
Institute of Pediatric Endocrinology, Dana Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
Background: The diagnosis of depression or anxiety treated by SSRIs has become relatively common in women of childbearing age. However, the impact of gestational SSRI treatment on newborn thyroid function is lacking. We explored the impact of gestational SSRI treatment on newborn thyroid function as measured by the National Newborn Screening (NBS) Program and identified contributory factors.
View Article and Find Full Text PDFAntidepressants versus placebo for generalised anxiety disorder (GAD).
Cochrane Database Syst Rev
January 2025
Department of Psychiatry and Department of Epidemiology and Biostatistics, Western University, St Thomas, Canada.
Background: Generalised anxiety disorder (GAD) is a mental health condition characterised by excessive anxiety and worry about everyday events. GAD is a common disorder and generally affects women twice as often as men. Treatments include various psychological and pharmacological therapies.
View Article and Find Full Text PDFNeurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction.
Front Psychiatry
January 2025
Xinjiang Clinical Medical Research Center of Mental Health, The Psychological Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Behavioral addictive disorders (BADs) have become a significant societal challenge over time. The central feature of BADs is the loss of control over engaging in and continuing behaviors, even when facing negative consequences. The neurobiological underpinnings of BADs primarily involve impairments in the reward circuitry, encompassing the ventral tegmental area, nucleus accumbens in the ventral striatum, and prefrontal cortex.
View Article and Find Full Text PDFThyroid Endocrine Disrupting Potential of Fluoxetine in Zebrafish Larvae.
J Appl Toxicol
January 2025
Changjiang Basin Ecology and Environment Monitoring and Scientific Research Center, Changjiang Basin Ecology and Environment Administration, Ministry of Ecology and Environment, Wuhan, China.
Fluoxetine (FLX), a typical selective serotonin reuptake inhibitors, has been frequently detected in aquatic environment and wild fish. However, little is known about its effect on thyroid endocrine system. In the present study, zebrafish (Danio rerio) embryos were exposed to 1, 3, 10, and 30 μg/L of FLX for 6 days.
View Article and Find Full Text PDFConfocal Endomicroscopy Intestinal Epithelial Barrier Abnormalities in Individuals Without Documented Gastro-Intestinal Disease.
United European Gastroenterol J
January 2025
Department of Gastroenterology, CHU Liège, Liège, Belgium.
Background And Aims: Probe-based confocal endomicroscopy (pCLE) allows real-time microscopic visualization of the intestinal mucosa surface layers. Despite remission achieved through anti-tumor necrosis factor or vedolizumab therapy, anomalies in the intestinal epithelial barrier are observed in inflammatory bowel disease (IBD) patients. Our study aimed to assess these abnormalities in non-IBD individuals and compare them with IBD patients in endoscopic remission to identify the associated factors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!